milrinone has been researched along with Coronary Heart Disease in 19 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Milrinone and dobutamine are positive inotropic agents with beneficial hemodynamic effects in patients with congestive heart failure." | 9.06 | Comparison of intravenous milrinone and dobutamine for congestive heart failure secondary to either ischemic or dilated cardiomyopathy. ( Benotti, JR; Biddle, TL; Creager, MA; Faxon, DP; Firth, BG; Fitzpatrick, PG; Kershner, RP; Konstam, MA; Krebs, C; Walton, L, 1987) |
| "The effects of MCI-154, a cardiotonic agent with Ca++ sensitizing actions, on the ischemic contractile failure and myocardial acidosis were studied in the dog heart, in which the left anterior descending coronary artery (LAD) was partially occluded for 90 min, and compared with those of dobutamine, milrinone, pimobendan and isosorbide dinitrate (ISDN)." | 7.68 | Beneficial effect of MCI-154, a cardiotonic agent, on ischemic contractile failure and myocardial acidosis of dog hearts: comparison with dobutamine, milrinone and pimobendan. ( Abe, Y; Kitada, Y; Narimatsu, A, 1992) |
| "Hemodynamics during 24-h dobutamine (dob) and subsequent 24-h milrinone (mil) infusion were studied in 20 patients (pts) with severe heart failure (NYHA III: 4 pts, NYHA IV: 16 pts)." | 7.68 | [Hemodynamics with dobutamine and milrinone in patients with severe heart failure in an intra-individual comparison]. ( Hilger, HH; Höpp, HW; Klocke, RK; Kux, A; Mager, G; Volkmann, A, 1991) |
| "To determine whether oral milrinone therapy has an effect on complex ventricular arrhythmias in patients with severe congestive heart failure and, if so, whether a change in the severity of complex ventricular arrhythmias after 1 week of milrinone therapy is associated with a change in the mode or frequency of cardiac mortality, a retrospective analysis was performed to determine the frequency of ventricular tachycardia and the density of ventricular couplets on 24-hour ambulatory electrocardiographic recordings performed before and 1 week after initiation of oral milrinone therapy in 74 consecutive patients with New York Heart Association functional class III or IV congestive heart failure." | 7.67 | Effects of milrinone on complex ventricular arrhythmias in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. ( Antman, EM; Baim, DS; Colucci, WS; Friedman, PL; Gauthier, DF; Ludmer, PL; Rocco, MB, 1987) |
| "Milrinone use is an independent risk factor for postoperative AF after elective cardiac surgery." | 6.73 | Milrinone use is associated with postoperative atrial fibrillation after cardiac surgery. ( Ball, SK; Brown, NJ; Byrne, JG; Fleming, GA; Greelish, JP; Hoff, SJ; Murray, KT; Petracek, MR; Pretorius, M; Yu, C, 2008) |
| "Milrinone and dobutamine are positive inotropic agents with beneficial hemodynamic effects in patients with congestive heart failure." | 5.06 | Comparison of intravenous milrinone and dobutamine for congestive heart failure secondary to either ischemic or dilated cardiomyopathy. ( Benotti, JR; Biddle, TL; Creager, MA; Faxon, DP; Firth, BG; Fitzpatrick, PG; Kershner, RP; Konstam, MA; Krebs, C; Walton, L, 1987) |
| "The effects of MCI-154, a cardiotonic agent with Ca++ sensitizing actions, on the ischemic contractile failure and myocardial acidosis were studied in the dog heart, in which the left anterior descending coronary artery (LAD) was partially occluded for 90 min, and compared with those of dobutamine, milrinone, pimobendan and isosorbide dinitrate (ISDN)." | 3.68 | Beneficial effect of MCI-154, a cardiotonic agent, on ischemic contractile failure and myocardial acidosis of dog hearts: comparison with dobutamine, milrinone and pimobendan. ( Abe, Y; Kitada, Y; Narimatsu, A, 1992) |
| "Hemodynamics during 24-h dobutamine (dob) and subsequent 24-h milrinone (mil) infusion were studied in 20 patients (pts) with severe heart failure (NYHA III: 4 pts, NYHA IV: 16 pts)." | 3.68 | [Hemodynamics with dobutamine and milrinone in patients with severe heart failure in an intra-individual comparison]. ( Hilger, HH; Höpp, HW; Klocke, RK; Kux, A; Mager, G; Volkmann, A, 1991) |
| "To determine whether oral milrinone therapy has an effect on complex ventricular arrhythmias in patients with severe congestive heart failure and, if so, whether a change in the severity of complex ventricular arrhythmias after 1 week of milrinone therapy is associated with a change in the mode or frequency of cardiac mortality, a retrospective analysis was performed to determine the frequency of ventricular tachycardia and the density of ventricular couplets on 24-hour ambulatory electrocardiographic recordings performed before and 1 week after initiation of oral milrinone therapy in 74 consecutive patients with New York Heart Association functional class III or IV congestive heart failure." | 3.67 | Effects of milrinone on complex ventricular arrhythmias in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. ( Antman, EM; Baim, DS; Colucci, WS; Friedman, PL; Gauthier, DF; Ludmer, PL; Rocco, MB, 1987) |
| "Milrinone use is an independent risk factor for postoperative AF after elective cardiac surgery." | 2.73 | Milrinone use is associated with postoperative atrial fibrillation after cardiac surgery. ( Ball, SK; Brown, NJ; Byrne, JG; Fleming, GA; Greelish, JP; Hoff, SJ; Murray, KT; Petracek, MR; Pretorius, M; Yu, C, 2008) |
| "Milrinone was administered intravenously in successive doses of 25, 50, and 75 micrograms/kg." | 2.66 | Milrinone in the treatment of chronic cardiac failure: a controlled trial. ( Andrews, V; Janicki, JS; Likoff, MJ; Rocci, ML; Weber, KT; Wilson, H, 1985) |
| "Milrinone was administered to 9 patients at the time of weaning from cardiopulmonary bypass, at a dosage of 3 to 5 micrograms/kg/min." | 1.31 | [The effects of intravenous milrinone for the patient undergoing CABG]. ( Cruz, BP; Komada, T; Maruyama, K; Okuda, M; Onoda, K; Shimono, T; Shimpo, H; Tanaka, K; Tokui, T; Utsunomiya, H; Yada, I; Yasuda, F, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (31.58) | 18.7374 |
| 1990's | 8 (42.11) | 18.2507 |
| 2000's | 5 (26.32) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fleming, GA | 1 |
| Murray, KT | 1 |
| Yu, C | 1 |
| Byrne, JG | 1 |
| Greelish, JP | 1 |
| Petracek, MR | 1 |
| Hoff, SJ | 1 |
| Ball, SK | 1 |
| Brown, NJ | 1 |
| Pretorius, M | 1 |
| Möllhoff, T | 1 |
| Schmidt, C | 1 |
| Van Aken, H | 1 |
| Berendes, E | 1 |
| Buerkle, H | 1 |
| Marmann, P | 1 |
| Reinbold, T | 1 |
| Prenger-Berninghoff, R | 1 |
| Tjan, TD | 1 |
| Scheld, HH | 1 |
| Deng, MC | 1 |
| Hill, JA | 1 |
| Hsu, K | 1 |
| Pauly, DF | 1 |
| Schofield, R | 1 |
| Aranda, JM | 1 |
| Yasuda, F | 1 |
| Shimono, T | 1 |
| Cruz, BP | 1 |
| Komada, T | 1 |
| Tokui, T | 1 |
| Onoda, K | 1 |
| Tanaka, K | 1 |
| Shimpo, H | 1 |
| Yada, I | 1 |
| Okuda, M | 1 |
| Utsunomiya, H | 1 |
| Maruyama, K | 1 |
| Shibata, T | 1 |
| Suehiro, S | 1 |
| Sasaki, Y | 1 |
| Hosono, M | 1 |
| Nishi, S | 1 |
| Kinoshita, H | 1 |
| Böhm, M | 3 |
| Gierschik, P | 2 |
| Erdmann, E | 3 |
| Abe, Y | 2 |
| Kitada, Y | 2 |
| Narimatsu, A | 2 |
| Ross-Ascuitto, NT | 1 |
| Ascuitto, RJ | 1 |
| Ramage, D | 1 |
| McDonough, KH | 1 |
| Mitrovic, V | 1 |
| Stöhring, R | 1 |
| Schlepper, M | 1 |
| Mager, G | 2 |
| Steffen, HM | 1 |
| Klocke, RK | 2 |
| Wambach, G | 1 |
| Kux, A | 2 |
| Degenhardt, S | 1 |
| Höpp, HW | 2 |
| Hilger, HH | 2 |
| Tobe, A | 1 |
| Volkmann, A | 1 |
| Jakobs, KH | 1 |
| Pieske, B | 1 |
| Schnabel, P | 1 |
| Ungerer, M | 1 |
| Diet, F | 1 |
| Feiler, G | 1 |
| Kemkes, B | 1 |
| Kreuzer, E | 1 |
| Weinhold, C | 1 |
| Holbrook, M | 1 |
| Coker, SJ | 1 |
| Lukas, A | 1 |
| Ferrier, GR | 1 |
| Biddle, TL | 1 |
| Benotti, JR | 1 |
| Creager, MA | 1 |
| Faxon, DP | 1 |
| Firth, BG | 1 |
| Fitzpatrick, PG | 1 |
| Konstam, MA | 1 |
| Krebs, C | 1 |
| Walton, L | 1 |
| Kershner, RP | 1 |
| Ludmer, PL | 1 |
| Baim, DS | 1 |
| Antman, EM | 1 |
| Gauthier, DF | 1 |
| Rocco, MB | 1 |
| Friedman, PL | 1 |
| Colucci, WS | 1 |
| Likoff, MJ | 1 |
| Weber, KT | 1 |
| Andrews, V | 1 |
| Janicki, JS | 1 |
| Wilson, H | 1 |
| Rocci, ML | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| RAAS, Inflammation, and Post-operative AF[NCT00141778] | Phase 2/Phase 3 | 455 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| 2- Inhaled Milrinone Prevents the Increase in Pulmonary Artery Pressure After CPB[NCT00819377] | Phase 2 | 124 participants (Anticipated) | Interventional | 2009-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Percentage of patients with a creatinine concentrations >2.5mg/dl (NCT00141778)
Timeframe: Measured until the time of hospital discharge, from 5.7 to 6.8 days on average, depending on the study group.
| Intervention | percentage of patients (Number) |
|---|---|
| Placebo | 5.4 |
| Ramipril | 0.7 |
| Spironolactone | 0.7 |
The percentage of patients in each study arm who died. (NCT00141778)
Timeframe: Measured until the time of hospital discharge
| Intervention | percentage of patients (Number) |
|---|---|
| Placebo | 1.4 |
| Ramipril | 2.0 |
| Spironolactone | 0 |
Percentage of patients who had a serum potassium concentrations <3.5 milliequivalents (mEq)/L (NCT00141778)
Timeframe: Measured until the time of hospital discharge, which was an average of 5.7 to 6.8 days depending on the treatment arm.
| Intervention | percentage of patients (Number) |
|---|---|
| Placebo | 11.6 |
| Ramipril | 13.8 |
| Spironolactone | 6.8 |
Percentage of patients with hypotension defined as a systolic blood pressure <90 mmHg and/or prolonged requirement for vasopressor use. (NCT00141778)
Timeframe: Measured during and after surgery, until discharge, from 5.7 to 6.8 days on average.
| Intervention | percentage of patients (Number) |
|---|---|
| Placebo | 5.4 |
| Ramipril | 10.6 |
| Spironolactone | 10.2 |
(NCT00141778)
Timeframe: Measured from the day of surgery until the time of hospital discharge
| Intervention | days (Mean) |
|---|---|
| Placebo | 6.8 |
| Ramipril | 5.7 |
| Spironolactone | 5.8 |
The primary endpoint of the study was the percentage of patients with electrocardiographically confirmed AF of at least 10 secs duration at any time following the end of surgery until hospital discharge, an average from 5.7 days in the ramipril group to 6.8 days in the placebo group. Patients were monitored continuously on telemetry throughout the postoperative period until discharge. Electrocardiograms were obtained for any rhythm changes detected on telemetry monitoring, and in addition, electrocardiograms were performed preoperatively, at admission to the intensive care unit, and daily starting on postoperative day 1. All electrocardiograms and rhythm strips were reviewed in a blinded fashion by a single cardiac electrophysiologist. (NCT00141778)
Timeframe: Measured from admission to the ICU until discharge from hospital
| Intervention | percentage of patients (Number) |
|---|---|
| Placebo | 27.2 |
| Ramipril | 27.8 |
| Spironolactone | 25.9 |
Percentage of patients in each study group who experience a cerebrovascular event, confirmed by CT. (NCT00141778)
Timeframe: Measured until the time of hospital discharge, from 5.7 to 6.8 days on average depending on the study arm.
| Intervention | percentage of patients (Number) |
|---|---|
| Placebo | 2.7 |
| Ramipril | 1.3 |
| Spironolactone | 2.0 |
It is the time in minutes that it took to extubate the patient after surgery. (NCT00141778)
Timeframe: It is the time (in minutes) from admission to the ICU until tracheal extubation
| Intervention | minutes (Mean) |
|---|---|
| Placebo | 1091.3 |
| Ramipril | 970.1 |
| Spironolactone | 576.4 |
C-reactive protein was measured at several time points (see table) over the course of the study. (NCT00141778)
Timeframe: Perioperative period
| Intervention | ug/mL (Mean) | ||||
|---|---|---|---|---|---|
| Initiation of surgery | Postoperative day 1 | Postoperative day 2 | Postoperative day 3 | Postoperative day 4 | |
| Placebo | 4.1 | 51.4 | 134.8 | 128.3 | 94.1 |
| Ramipril | 4.3 | 49.9 | 131.0 | 164.8 | 105.2 |
| Spironolactone | 3.9 | 64.3 | 127.8 | 189.4 | 126.5 |
Interleukin-6 was measured at several time points (see time points in table) over the course of the study (NCT00141778)
Timeframe: Perioperative period
| Intervention | pg/ml (Mean) | |||||
|---|---|---|---|---|---|---|
| Initiation of surgery | 30min intraop | 60min intraop | Postop | Postoperative day 1 | Postoperative day 2 | |
| Placebo | 4.7 | 12.0 | 15.6 | 130.0 | 119.0 | 100.3 |
| Ramipril | 4.6 | 20.5 | 28.8 | 202.1 | 171.0 | 95.5 |
| Spironolactone | 6.6 | 11.3 | 17.4 | 145.7 | 164.9 | 109.6 |
Plasminogen activator inhibitor-1 (PAI-1) was measured at several time points (see table) over the course of the study. (NCT00141778)
Timeframe: Perioperative period
| Intervention | ng/mL (Mean) | |||||
|---|---|---|---|---|---|---|
| Initiation of surgery | 30min intraop | 60min intraop | Postop | Postoperative day 1 | Postoperative day 2 | |
| Placebo | 19.6 | 19.2 | 21.0 | 36.4 | 55.2 | 28.1 |
| Ramipril | 16.2 | 19.7 | 22.0 | 38.9 | 47.9 | 25.7 |
| Spironolactone | 17.3 | 17.3 | 20.1 | 34.0 | 48.9 | 31.0 |
7 trials available for milrinone and Coronary Heart Disease
| Article | Year |
|---|---|
Milrinone use is associated with postoperative atrial fibrillation after cardiac surgery.
Topics: Adult; Aged; Atrial Fibrillation; Cardiac Surgical Procedures; Cardiotonic Agents; Coronary Disease; | 2008 |
Myocardial ischaemia in patients with impaired left ventricular function undergoing coronary artery bypass grafting--milrinone versus nifedipin.
Topics: Aged; Anesthesia, General; Calcium Channel Blockers; Coronary Artery Bypass; Coronary Disease; Creat | 2002 |
Slow induction of milrinone after coronary artery bypass grafting.
Topics: Aged; Cardiotonic Agents; Coronary Artery Bypass; Coronary Circulation; Coronary Disease; Female; He | 2001 |
The use of intravenous milrinone in chronic symptomatic ischemic heart disease.
Topics: Aged; Angina Pectoris; Atrial Natriuretic Factor; Cardiotonic Agents; Coronary Disease; Drug Evaluat | 1991 |
[The effect of hemodynamic changes in 24-hour milrinone infusion on sympathetic activity and the renin-angiotensin-aldosterone system in patients with severe heart failure].
Topics: Adult; Cardiomyopathy, Dilated; Cardiotonic Agents; Catecholamines; Coronary Disease; Drug Administr | 1991 |
Comparison of intravenous milrinone and dobutamine for congestive heart failure secondary to either ischemic or dilated cardiomyopathy.
Topics: Cardiomyopathy, Dilated; Coronary Disease; Dobutamine; Heart Failure; Hemodynamics; Humans; Infusion | 1987 |
Milrinone in the treatment of chronic cardiac failure: a controlled trial.
Topics: Administration, Oral; Aged; Atrial Fibrillation; Cardiomyopathy, Dilated; Chronic Disease; Clinical | 1985 |
12 other studies available for milrinone and Coronary Heart Disease
| Article | Year |
|---|---|
Sustained use of nesiritide to aid in bridging to heart transplant.
Topics: Adult; Cardiomyopathy, Dilated; Cardiotonic Agents; Coronary Disease; Diuretics; Dobutamine; Dopamin | 2003 |
[The effects of intravenous milrinone for the patient undergoing CABG].
Topics: Aged; Cardiotonic Agents; Coronary Artery Bypass; Coronary Disease; Female; Hemodynamics; Humans; In | 2000 |
Quantification of Gi alpha-proteins in the failing and nonfailing human myocardium.
Topics: Amino Acid Sequence; Antibodies; Cardiomyopathy, Dilated; Coronary Disease; GTP-Binding Proteins; He | 1992 |
Beneficial effect of MCI-154, a cardiotonic agent, on ischemic contractile failure and myocardial acidosis of dog hearts: comparison with dobutamine, milrinone and pimobendan.
Topics: Acidosis; Animals; Cardiotonic Agents; Coronary Disease; Dobutamine; Dogs; Female; Hemodynamics; Hyd | 1992 |
The effects of milrinone in the neonatal pig heart.
Topics: 1-Methyl-3-isobutylxanthine; Animals; Animals, Newborn; Cells, Cultured; Coronary Circulation; Coron | 1991 |
Improvement of postischemic contractile dysfunction of dog heart by MCI-154, a novel cardiotonic agent.
Topics: Adenosine Triphosphate; Animals; Calcium; Cardiotonic Agents; Coronary Disease; Dobutamine; Dogs; Fe | 1991 |
[Hemodynamics with dobutamine and milrinone in patients with severe heart failure in an intra-individual comparison].
Topics: Adult; Aged; Cardiomyopathy, Dilated; Cardiotonic Agents; Coronary Disease; Dobutamine; Dose-Respons | 1991 |
Increase of Gi alpha in human hearts with dilated but not ischemic cardiomyopathy.
Topics: Adenosine Diphosphate Ribose; Adenylate Cyclase Toxin; Adenylyl Cyclases; Adult; Carbachol; Cardiomy | 1990 |
Subsensitivity of the failing human heart to isoprenaline and milrinone is related to beta-adrenoceptor downregulation.
Topics: Aging; Cardiotonic Agents; Coronary Disease; Electric Stimulation; Heart Failure; Humans; In Vitro T | 1988 |
Comparison of the effects of isobutylmethylxanthine and milrinone on ischaemia-induced arrhythmias and platelet aggregation in anaesthetized rabbits.
Topics: 1-Methyl-3-isobutylxanthine; Anesthesia; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bloo | 1989 |
Electrophysiological effects of amrinone and milrinone in an isolated canine cardiac tissue model of ischemia and reperfusion.
Topics: Amrinone; Animals; Coronary Disease; Dogs; Electrophysiology; Heart Conduction System; Male; Milrino | 1988 |
Effects of milrinone on complex ventricular arrhythmias in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
Topics: Adult; Aged; Ambulatory Care; Arrhythmias, Cardiac; Cardiomyopathy, Dilated; Coronary Disease; Elect | 1987 |